ADVFN Logo ADVFN

Hot Features

Registration Strip Icon for discussion Inscrivez-vous pour interagir sur nos forums actifs pour discuter avec des investisseurs aux idées similaires.
Lisata Therapeutics Inc

Lisata Therapeutics Inc (LSTA)

2,8438
-0,0862
(-2,94%)
À la fermeture: 21 Novembre 10:00PM
2,8438
0,00
( 0,00% )
Après les heures de négociation: 10:07PM

Outils de qualité professionnelle, pour des investisseurs individuels.

Statistiques et détails clés

Dernier
2,8438
Prix Achat
2,80
Prix Vente
3,54
Volume échangé
5 986
2,8206 Fourchette du Jour 2,93
2,05 Plage de 52 semaines 3,83
Cap du marché
Clôture Veille
2,93
Ouverture
2,92
Dernière Transaction
1
@
2.82
Dernière heure de transaction
22:00:02
Volume financier
US$ 17 343
VWAP
2,8973
Volume moyen (3 m)
14 222
Actions en circulation
8 394 903
Rendement du Dividende
-
Ratio Cours sur Bénéfices
-1,14
Bénéfice par action (BPA)
-2,48
Chiffre d'affairess
-
Bénéfice net
-20,84M

À propos de Lisata Therapeutics Inc

Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. Lisata Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases.

Secteur
Health & Allied Services,nec
Industrie
Insurance Carriers, Nec
Siège social
Wilmington, Delaware, USA
Fondé
2006
Lisata Therapeutics Inc est coté dans le secteur Health & Allied Services de la NASDAQ avec le ticker LSTA. Le dernier cours de clôture d'Lisata Therapeutics était de US$2,93. Au cours de la dernière année, les actions de Lisata Therapeutics ont été négociées dans une fourchette de prix de US$ 2,05 à US$ 3,83.

Lisata Therapeutics compte actuellement 8 394 903 actions en circulation. La capitalisation boursière d'Lisata Therapeutics est de US$24,60 million. Lisata Therapeutics a un ratio cours/bénéfice (ratio PE) de -1.14.

LSTA Dernières nouvelles

Lisata Therapeutics Wins 2024 BioTech Breakthrough Award for ‘Specialized BioTherapeutics Company of the Year’

Award recognizes Lisata’s data-driven approach and innovative therapies designed to address the unmet medical needs of patients with advanced solid tumors Annual BioTech Breakthrough Award is...

Lisata Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Robust and expanding development portfolio with multiple key data readouts projected over the next 18 months Conference call scheduled for today at 4:30 p.m. Eastern Time BASKING RIDGE, N.J...

Lisata Therapeutics and Valo Therapeutics Announce Preclinical Research Collaboration

BASKING RIDGE, N.J. and HELSINKI, Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the...

Lisata Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Business Update on Tuesday, November 12, 2024

BASKING RIDGE, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of...

Lisata Therapeutics to Participate in Upcoming November 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of...

Lisata Therapeutics Announces Sponsored Preclinical Research Agreement with the University of Cincinnati to Study Certepetide for the Treatment of Endometriosis

BASKING RIDGE, N.J., Oct. 28, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA), a clinical-stage pharmaceutical company developing innovative therapies for the treatment of...

Lisata Therapeutics to Participate in Upcoming October 2024 Industry and Investor Events

BASKING RIDGE, N.J., Oct. 03, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics Announces First Patient Treated in the Second-line Cholangiocarcinoma Cohort of the BOLSTER Trial

BASKING RIDGE, N.J., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics to Participate in Upcoming September 2024 Industry and Investor Events

BASKING RIDGE, N.J. , Sept. 09, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

Lisata Therapeutics’ Certepetide Granted FDA Orphan Drug Designation for the Treatment of Cholangiocarcinoma

BASKING RIDGE, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata” or the “Company”), a clinical-stage pharmaceutical company developing innovative...

PériodeVariationVariation %Ouver.HautBasMoyenne Vol. Quot.VWAP
10.00380.1338028169012.843.12.6909288612.82623679CS
4-0.0762-2.60958904112.923.352.6909191942.90426728CS
120.04381.564285714292.83.352.6909142222.95946825CS
26-0.0162-0.5664335664342.863.832.6909155513.16846534CS
520.643829.26363636362.23.832.05147293.03482001CS
156-5.9562-67.68409090918.89.381.95217543.77073791CS
260-5.9562-67.68409090918.89.381.95217543.77073791CS

Moteurs

Voir tout
  • Volume
  • % Gagnants
  • % Perdants
SymbolePrixVol.
MTEMMolecular Templates Inc
US$ 0,5683
(49,55%)
1,9M
SKKSKK Holdings Limited
US$ 1,15
(13,86%)
636,87k
EYENEyenovia Inc
US$ 0,119
(13,23%)
351,94k
TFFPTFF Pharmaceuticals Inc
US$ 0,39
(11,30%)
259,75k
VRPXVirpax Pharmaceuticals Inc
US$ 0,64
(9,93%)
6,06k
VLCNVolcon Inc
US$ 4,3778
(-9,85%)
300
INTUIntuit Inc
US$ 618,47
(-8,89%)
68,7k
BDRXBiodexa Pharmaceuticals PLC
US$ 4,30
(-8,51%)
926
AHGAkso Health Group
US$ 0,81
(-8,01%)
299
GRNQGreenpro Capital Corporation
US$ 1,20
(-7,69%)
15,21k
MTEMMolecular Templates Inc
US$ 0,5683
(49,55%)
1,9M
IBITiShares Bitcoin Trust ETF
US$ 55,79
(-0,25%)
1,07M
NVDANVIDIA Corporation
US$ 146,27
(-0,25%)
1,06M
OPENOpendoor Technologies Inc
US$ 1,69
(-1,74%)
815,98k
QQQMInvesco NASDAQ 100 ETF
US$ 207,9131
(0,03%)
780,93k
Aucune Discussion Trouvée
Ajouter une Discussion

Dernières Valeurs Consultées

Delayed Upgrade Clock